1. Home
  2. PCRX vs CCOI Comparison

PCRX vs CCOI Comparison

Compare PCRX & CCOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$26.12

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Cogent Communications Holdings Inc.

CCOI

Cogent Communications Holdings Inc.

HOLD

Current Price

$22.50

Market Cap

1.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
CCOI
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
CCOI
Price
$26.12
$22.50
Analyst Decision
Strong Buy
Hold
Analyst Count
7
8
Target Price
$32.86
$30.25
AVG Volume (30 Days)
885.6K
1.3M
Earning Date
02-26-2026
02-26-2026
Dividend Yield
N/A
18.35%
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$716,791,000.00
$907,233,000.00
Revenue This Year
$6.24
$4.50
Revenue Next Year
$9.53
$2.63
P/E Ratio
$55.17
N/A
Revenue Growth
3.14
N/A
52 Week Low
$18.18
$15.96
52 Week High
$27.64
$84.06

Technical Indicators

Market Signals
Indicator
PCRX
CCOI
Relative Strength Index (RSI) 56.85 51.24
Support Level $24.20 $19.38
Resistance Level $26.48 $22.86
Average True Range (ATR) 0.98 1.08
MACD -0.11 0.20
Stochastic Oscillator 68.10 83.24

Price Performance

Historical Comparison
PCRX
CCOI

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About CCOI Cogent Communications Holdings Inc.

Cogent carries over one-fifth of the world's internet traffic on its network, providing high-capacity services to businesses. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking, which offers an internal network for employees in different locations. Cogent's corporate customers are exclusively in North America and account for nearly half of the firm's revenue. Cogent's netcentric customers include internet service providers and content providers, to which Cogent provides internet transit. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US.

Share on Social Networks: